BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15762372)

  • 1. [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer].
    Longo F; Mansueto G
    Tumori; 2004; 90(6):1-12. PubMed ID: 15762372
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Wenz F
    N Engl J Med; 2009 May; 360(22):2367; author reply 2369-70. PubMed ID: 19474438
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant aromatase inhibitors for breast cancer.
    Howell A
    Lancet; 2005 Aug 6-12; 366(9484):431-3. PubMed ID: 16084234
    [No Abstract]   [Full Text] [Related]  

  • 4. Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
    [No Abstract]   [Full Text] [Related]  

  • 5. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
    Buzdar AU
    J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830
    [No Abstract]   [Full Text] [Related]  

  • 6. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Berruti A; Buttigliero C; Dogliotti L
    N Engl J Med; 2009 May; 360(22):2368; author reply 2369-70. PubMed ID: 19484817
    [No Abstract]   [Full Text] [Related]  

  • 7. Breast cancer (metastatic).
    Stebbing J; Crane J; Gaya A
    Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
    [No Abstract]   [Full Text] [Related]  

  • 8. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
    Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
    Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERBB2 status and outcome of endocrine treatment.
    Miller WR
    Lancet Oncol; 2008 Jan; 9(1):4-5. PubMed ID: 18177812
    [No Abstract]   [Full Text] [Related]  

  • 10. Obesity and hormone therapy in breast cancer: an unfinished puzzle.
    Goodwin PJ; Pritchard KI
    J Clin Oncol; 2010 Jul; 28(21):3405-7. PubMed ID: 20548001
    [No Abstract]   [Full Text] [Related]  

  • 11. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gelber RD; Aebi S
    N Engl J Med; 2009 May; 360(22):2367; author reply 2369-70. PubMed ID: 19484813
    [No Abstract]   [Full Text] [Related]  

  • 12. [Advancement in endocrine therapy for breast cancer].
    Yang MT; Lian ZQ
    Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
    Johnston SR
    Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
    Chlebowski R; Cuzick J; Amakye D; Bauerfeind I; Buzdar A; Chia S; Cutuli B; Linforth R; Maass N; Noguchi S; Robidoux A; Verma S; Hadji P
    Breast; 2009 Aug; 18 Suppl 2():S1-11. PubMed ID: 19712865
    [No Abstract]   [Full Text] [Related]  

  • 16. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of aromatase inhibition for breast cancer.
    Toi M
    Lancet Oncol; 2008 Jan; 9(1):8-10. PubMed ID: 18177815
    [No Abstract]   [Full Text] [Related]  

  • 18. ATAC trial update.
    de Castro G
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
    [No Abstract]   [Full Text] [Related]  

  • 19. Antihormone therapy in recurrent metastatic breast cancer.
    Pritchard KI
    JAMA; 2008 Jun; 299(23):2745; author reply 2745. PubMed ID: 18559999
    [No Abstract]   [Full Text] [Related]  

  • 20. Letrozole: advancing hormone therapy in breast cancer.
    Lee RJ; Armstrong AC; Wardley AM
    Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.